Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS
Background: The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall ou...
Gespeichert in:
| Veröffentlicht in: | Journal of intensive care medicine 2021-06, Vol.36 (6), p.681-688 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 688 |
|---|---|
| container_issue | 6 |
| container_start_page | 681 |
| container_title | Journal of intensive care medicine |
| container_volume | 36 |
| creator | Häberle, Helene Magunia, Harry Lang, Peter Gloeckner, Henning Körner, Andreas Koeppen, Michael Backchoul, Tamam Malek, Nisar Handgretinger, Rupert Rosenberger, Peter Mirakaj, Valbona |
| description | Background:
The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall outcome in patients with severe COVID-19 ARDS. We offered MSC infusion as an extended indication to all critically ill COVID-19 patients with a Horovitz index |
| doi_str_mv | 10.1177/0885066621997365 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8145440</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0885066621997365</sage_id><sourcerecordid>2498479770</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-c733969dc31cf62a8e206a2295bede63e155b1b0a9119d2c0682f19dc5eb949e3</originalsourceid><addsrcrecordid>eNp1kMtPwkAQxjdGI4jePZkevVT33e7FhIAPEgyJoNfNdjuFkj5wt5Dw31sCEjXxNJN833wz80PomuA7QqLoHsexwFJKSpSKmBQnqEsEFSHhsTpF3Z0c7vQOuvB-iTFhlJFz1GFMSkY57yL5Ch4qu9iWpgimDZTBAIoimC3AmdU2yGoXTGEDDoLB5GM0DIkK-m_D6SU6y0zh4epQe-j96XE2eAnHk-fRoD8OLWe8CW3EmJIqtYzYTFITA8XSUKpEAilIBkSIhCTYKEJUSi2WMc3azgpIFFfAeuhhn7taJyWkFqrGmUKvXF4at9W1yfVvpcoXel5vdEy44By3AbeHAFd_rsE3usy9bV80FdRrrylXMY9UFO2seG-1rvbeQXZcQ7De4dZ_cbcjNz_POw58820N4d7gzRz0sl67qsX1f-AXFKiFpA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2498479770</pqid></control><display><type>article</type><title>Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Häberle, Helene ; Magunia, Harry ; Lang, Peter ; Gloeckner, Henning ; Körner, Andreas ; Koeppen, Michael ; Backchoul, Tamam ; Malek, Nisar ; Handgretinger, Rupert ; Rosenberger, Peter ; Mirakaj, Valbona</creator><creatorcontrib>Häberle, Helene ; Magunia, Harry ; Lang, Peter ; Gloeckner, Henning ; Körner, Andreas ; Koeppen, Michael ; Backchoul, Tamam ; Malek, Nisar ; Handgretinger, Rupert ; Rosenberger, Peter ; Mirakaj, Valbona</creatorcontrib><description>Background:
The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall outcome in patients with severe COVID-19 ARDS. We offered MSC infusion as an extended indication to all critically ill COVID-19 patients with a Horovitz index <100. We treated 5 out of 23 patients with severe COVID-19 ARDS with an infusion of MSCs. One million MSCs/kg body weight was infused over 30 minutes, and the process was repeated in 3 patients twice and in 2 patients 3 times.
Result:
Four out of 5 MSC-treated patients compared to 50% of control patients (9 out of 18) received ECMO support (80%). The MSC group showed a higher Murray score on admission than control patients, reflecting more severe pulmonary compromise (3.5 ± 0.2 versus 2.8 ± 0.3). MSC infusion was safe and well tolerated. The MSC group had a significantly higher Horovitz score on discharge than the control group. Compared to controls, patients with MSC treatment showed a significantly lower Murray score upon discharge than controls. In the MSC group, 4 out of 5 patients (80%) survived to discharge and exhibited good pulmonary function, whereas only 8 out of 18 patients (45%) in the control group survived to discharge.
Conclusion:
MSC infusion is a safe treatment for COVID-19 ARDS that improves pulmonary function and overall outcome in this patient population.</description><identifier>ISSN: 0885-0666</identifier><identifier>EISSN: 1525-1489</identifier><identifier>DOI: 10.1177/0885066621997365</identifier><identifier>PMID: 33663244</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Aged ; Cohort Studies ; COVID-19 - complications ; COVID-19 - mortality ; COVID-19 - therapy ; Critical Care ; Female ; Germany ; Humans ; Male ; Mesenchymal Stem Cell Transplantation ; Middle Aged ; Original Research ; Respiration, Artificial ; Respiratory Distress Syndrome - mortality ; Respiratory Distress Syndrome - therapy ; Respiratory Distress Syndrome - virology ; Survival Rate ; Treatment Outcome</subject><ispartof>Journal of intensive care medicine, 2021-06, Vol.36 (6), p.681-688</ispartof><rights>The Author(s) 2021</rights><rights>The Author(s) 2021 2021 SAGE Publications</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-c733969dc31cf62a8e206a2295bede63e155b1b0a9119d2c0682f19dc5eb949e3</citedby><cites>FETCH-LOGICAL-c434t-c733969dc31cf62a8e206a2295bede63e155b1b0a9119d2c0682f19dc5eb949e3</cites><orcidid>0000-0001-9576-6399 ; 0000-0002-9643-7498</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0885066621997365$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0885066621997365$$EHTML$$P50$$Gsage$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33663244$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Häberle, Helene</creatorcontrib><creatorcontrib>Magunia, Harry</creatorcontrib><creatorcontrib>Lang, Peter</creatorcontrib><creatorcontrib>Gloeckner, Henning</creatorcontrib><creatorcontrib>Körner, Andreas</creatorcontrib><creatorcontrib>Koeppen, Michael</creatorcontrib><creatorcontrib>Backchoul, Tamam</creatorcontrib><creatorcontrib>Malek, Nisar</creatorcontrib><creatorcontrib>Handgretinger, Rupert</creatorcontrib><creatorcontrib>Rosenberger, Peter</creatorcontrib><creatorcontrib>Mirakaj, Valbona</creatorcontrib><title>Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS</title><title>Journal of intensive care medicine</title><addtitle>J Intensive Care Med</addtitle><description>Background:
The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall outcome in patients with severe COVID-19 ARDS. We offered MSC infusion as an extended indication to all critically ill COVID-19 patients with a Horovitz index <100. We treated 5 out of 23 patients with severe COVID-19 ARDS with an infusion of MSCs. One million MSCs/kg body weight was infused over 30 minutes, and the process was repeated in 3 patients twice and in 2 patients 3 times.
Result:
Four out of 5 MSC-treated patients compared to 50% of control patients (9 out of 18) received ECMO support (80%). The MSC group showed a higher Murray score on admission than control patients, reflecting more severe pulmonary compromise (3.5 ± 0.2 versus 2.8 ± 0.3). MSC infusion was safe and well tolerated. The MSC group had a significantly higher Horovitz score on discharge than the control group. Compared to controls, patients with MSC treatment showed a significantly lower Murray score upon discharge than controls. In the MSC group, 4 out of 5 patients (80%) survived to discharge and exhibited good pulmonary function, whereas only 8 out of 18 patients (45%) in the control group survived to discharge.
Conclusion:
MSC infusion is a safe treatment for COVID-19 ARDS that improves pulmonary function and overall outcome in this patient population.</description><subject>Adult</subject><subject>Aged</subject><subject>Cohort Studies</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - mortality</subject><subject>COVID-19 - therapy</subject><subject>Critical Care</subject><subject>Female</subject><subject>Germany</subject><subject>Humans</subject><subject>Male</subject><subject>Mesenchymal Stem Cell Transplantation</subject><subject>Middle Aged</subject><subject>Original Research</subject><subject>Respiration, Artificial</subject><subject>Respiratory Distress Syndrome - mortality</subject><subject>Respiratory Distress Syndrome - therapy</subject><subject>Respiratory Distress Syndrome - virology</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0885-0666</issn><issn>1525-1489</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><recordid>eNp1kMtPwkAQxjdGI4jePZkevVT33e7FhIAPEgyJoNfNdjuFkj5wt5Dw31sCEjXxNJN833wz80PomuA7QqLoHsexwFJKSpSKmBQnqEsEFSHhsTpF3Z0c7vQOuvB-iTFhlJFz1GFMSkY57yL5Ch4qu9iWpgimDZTBAIoimC3AmdU2yGoXTGEDDoLB5GM0DIkK-m_D6SU6y0zh4epQe-j96XE2eAnHk-fRoD8OLWe8CW3EmJIqtYzYTFITA8XSUKpEAilIBkSIhCTYKEJUSi2WMc3azgpIFFfAeuhhn7taJyWkFqrGmUKvXF4at9W1yfVvpcoXel5vdEy44By3AbeHAFd_rsE3usy9bV80FdRrrylXMY9UFO2seG-1rvbeQXZcQ7De4dZ_cbcjNz_POw58820N4d7gzRz0sl67qsX1f-AXFKiFpA</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Häberle, Helene</creator><creator>Magunia, Harry</creator><creator>Lang, Peter</creator><creator>Gloeckner, Henning</creator><creator>Körner, Andreas</creator><creator>Koeppen, Michael</creator><creator>Backchoul, Tamam</creator><creator>Malek, Nisar</creator><creator>Handgretinger, Rupert</creator><creator>Rosenberger, Peter</creator><creator>Mirakaj, Valbona</creator><general>SAGE Publications</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9576-6399</orcidid><orcidid>https://orcid.org/0000-0002-9643-7498</orcidid></search><sort><creationdate>20210601</creationdate><title>Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS</title><author>Häberle, Helene ; Magunia, Harry ; Lang, Peter ; Gloeckner, Henning ; Körner, Andreas ; Koeppen, Michael ; Backchoul, Tamam ; Malek, Nisar ; Handgretinger, Rupert ; Rosenberger, Peter ; Mirakaj, Valbona</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-c733969dc31cf62a8e206a2295bede63e155b1b0a9119d2c0682f19dc5eb949e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Cohort Studies</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - mortality</topic><topic>COVID-19 - therapy</topic><topic>Critical Care</topic><topic>Female</topic><topic>Germany</topic><topic>Humans</topic><topic>Male</topic><topic>Mesenchymal Stem Cell Transplantation</topic><topic>Middle Aged</topic><topic>Original Research</topic><topic>Respiration, Artificial</topic><topic>Respiratory Distress Syndrome - mortality</topic><topic>Respiratory Distress Syndrome - therapy</topic><topic>Respiratory Distress Syndrome - virology</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Häberle, Helene</creatorcontrib><creatorcontrib>Magunia, Harry</creatorcontrib><creatorcontrib>Lang, Peter</creatorcontrib><creatorcontrib>Gloeckner, Henning</creatorcontrib><creatorcontrib>Körner, Andreas</creatorcontrib><creatorcontrib>Koeppen, Michael</creatorcontrib><creatorcontrib>Backchoul, Tamam</creatorcontrib><creatorcontrib>Malek, Nisar</creatorcontrib><creatorcontrib>Handgretinger, Rupert</creatorcontrib><creatorcontrib>Rosenberger, Peter</creatorcontrib><creatorcontrib>Mirakaj, Valbona</creatorcontrib><collection>SAGE Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of intensive care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Häberle, Helene</au><au>Magunia, Harry</au><au>Lang, Peter</au><au>Gloeckner, Henning</au><au>Körner, Andreas</au><au>Koeppen, Michael</au><au>Backchoul, Tamam</au><au>Malek, Nisar</au><au>Handgretinger, Rupert</au><au>Rosenberger, Peter</au><au>Mirakaj, Valbona</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS</atitle><jtitle>Journal of intensive care medicine</jtitle><addtitle>J Intensive Care Med</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>36</volume><issue>6</issue><spage>681</spage><epage>688</epage><pages>681-688</pages><issn>0885-0666</issn><eissn>1525-1489</eissn><abstract>Background:
The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether the infusion of mesenchymal stromal cells (MSCs) would help to improve pulmonary function and overall outcome in patients with severe COVID-19 ARDS. We offered MSC infusion as an extended indication to all critically ill COVID-19 patients with a Horovitz index <100. We treated 5 out of 23 patients with severe COVID-19 ARDS with an infusion of MSCs. One million MSCs/kg body weight was infused over 30 minutes, and the process was repeated in 3 patients twice and in 2 patients 3 times.
Result:
Four out of 5 MSC-treated patients compared to 50% of control patients (9 out of 18) received ECMO support (80%). The MSC group showed a higher Murray score on admission than control patients, reflecting more severe pulmonary compromise (3.5 ± 0.2 versus 2.8 ± 0.3). MSC infusion was safe and well tolerated. The MSC group had a significantly higher Horovitz score on discharge than the control group. Compared to controls, patients with MSC treatment showed a significantly lower Murray score upon discharge than controls. In the MSC group, 4 out of 5 patients (80%) survived to discharge and exhibited good pulmonary function, whereas only 8 out of 18 patients (45%) in the control group survived to discharge.
Conclusion:
MSC infusion is a safe treatment for COVID-19 ARDS that improves pulmonary function and overall outcome in this patient population.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>33663244</pmid><doi>10.1177/0885066621997365</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9576-6399</orcidid><orcidid>https://orcid.org/0000-0002-9643-7498</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-0666 |
| ispartof | Journal of intensive care medicine, 2021-06, Vol.36 (6), p.681-688 |
| issn | 0885-0666 1525-1489 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8145440 |
| source | Access via SAGE; MEDLINE |
| subjects | Adult Aged Cohort Studies COVID-19 - complications COVID-19 - mortality COVID-19 - therapy Critical Care Female Germany Humans Male Mesenchymal Stem Cell Transplantation Middle Aged Original Research Respiration, Artificial Respiratory Distress Syndrome - mortality Respiratory Distress Syndrome - therapy Respiratory Distress Syndrome - virology Survival Rate Treatment Outcome |
| title | Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A39%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mesenchymal%20Stem%20Cell%20Therapy%20for%20Severe%20COVID-19%20ARDS&rft.jtitle=Journal%20of%20intensive%20care%20medicine&rft.au=H%C3%A4berle,%20Helene&rft.date=2021-06-01&rft.volume=36&rft.issue=6&rft.spage=681&rft.epage=688&rft.pages=681-688&rft.issn=0885-0666&rft.eissn=1525-1489&rft_id=info:doi/10.1177/0885066621997365&rft_dat=%3Cproquest_pubme%3E2498479770%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2498479770&rft_id=info:pmid/33663244&rft_sage_id=10.1177_0885066621997365&rfr_iscdi=true |